Edwin Lim

EM Pharmacist @stanfordhealth by way of @northwesternmed and @ucsfhospitals. @jeffersonuniv grad. Views are my own.

[Edwin Lim @EdintheED]

@GilbertPharmD @PulmCrit basically ESETT was the first RCT that actually used the 60 mg/kg

[Edwin Lim @EdintheED]

@GilbertPharmD @PulmCrit pretty sure the dose started being used after the recommendation from the Glauser et al. 2016 status epilepticus guidelines. however, the only cited recommendation for that dose was from Goraya et al., which was case series report with varying doses of keppra in pediatric pts.

[Christian Hamm, PharmD, BCPS @NamastePharmD]

Stanford Health Care will have an ED Pharmacist position opening soon!

Please alert anyone that might be interested and message me directly for more info.

Thanks. 🙏

[Brian Dang @DangEMPharm]

💊💉 Happy Pharmacy Week!💊💉

Join us for the 🌲Stanford🌲Pharmacy Residency Showcase (PGY1s and PGY2s) this week and next month!

RSVP with link below 👇🏼

https://t.co/jyif4t1pZ8

[Edwin Lim @EdintheED]

@DangEMPharm @jennlepharm @StanfordEMED

[Brian Dang @DangEMPharm]

📣Attn: Pharmacy Residency Candidates📣

Come check out the 🎄Stanford 🎄Pharmacy Residency Programs (PGY1, EM, Crit Care, Heme/Onc, HSPAL) tomorrow morning (08:00-11:00) at #ashpmidyear residency showcase Booth 5169

@ASHPOfficial @ASHP_EMPharm

[Jennifer Le @jennlepharm]

Our second open house is this Friday 11/18 from 5-7pm PST!

Come by to learn more about SHC’s pharmacy residency programs, meet our program directors and coordinators, and chat with the current residents!

Link to sign up:
https://t.co/hjsta2lw8p

[Sara J. Hyland @SaraJPharmD]

Very interesting study and great work by a pharmacist-led interprofessional research team! 👏👏👏
https://t.co/ZKHxSdAnZ4

[Brian Dang @DangEMPharm]

Stanford is hosting a Pharmacy Residency Virtual Open House!

Check out our PGY-1 (Acute Care, Amb Care, TOC, Specialty) and PGY-2 (Critical Care, EM, HSPAL, Hem/Onc, ID) programs!

Sign up below:
https://t.co/rxR9hVxKVM

[Chilla PharmD, BCEMP @ChillaPharmD]

🚨🚨Spoiler alert: Andexxa no better than Kcentra for ICH 🧠🩸 associated with apixaban or rivaroxaban.

💉💸🔥🗑🔥

Level of excellent hemostasis achieved after AA= 71.1%, 4F-PCC= 70.7%❗️

https://t.co/mwcSj19iUm

[David Juurlink @DavidJuurlink]

Just found a very, very good review of antiseizure drugs https://t.co/XSpTwNGKB0

[Andy Webb @AJWPharm]

We've had a few patients with mitochondrial diseases recently and I've had to refresh myself on the details of the ol powerhouses of the cell.

While each disease is unique, there is a common set of meds to avoid. I put together a 1-pager for common ones!

#NeuroCritCare

[Bryan D Hayes PharmD @PharmERToxGuy]

Wow! Props to the gastroenterology groups for suggesting against the use of high-cost reversal agents in many GI bleeding scenarios based on a lack of high-quality data.

https://t.co/IPg369CUdP

[Academic Life in EM @ALiEMteam]

How long after taking a DOAC can patients safely receive a thrombolytic? Learn more in this EM Pharm Pearl!

https://t.co/NFm7rgWcFC

@MikeEMPharmD @PharmERToxGuy

[Joe Bellezzo MD || Emergency Physician @drbellezzo]

They finally did the study!

[Edwin Lim @EdintheED]

@HemeOncPharmD @HOPArx @StanfordHealth @StanfordBMT_CT 👏👏👏

[Scott Dietrich @PCC_PharmD]

4PCC + Andexxa is so dumb. So expensive, no proven benefit of the combo, and looks like a VERY high thromboembolism rate of 35-40%

https://t.co/IYRSTGO4xF

[Brian Dang @DangEMPharm]

Whoaaa ANEXXA-S terminated 👀👀

[Edwin Lim @EdintheED]

@EMthorp_pharmd tiger zoo owner rn (probably)